local_hospital

Stichting Martini Ziekenhuis

Address
Van Swietenplein 1, 9728 NT Groningen, The Netherlands

Cardiovascular Research

At Stichting Martini Ziekenhuis in Groningen, the Cardio Research Noord team is active in cardiovascular diseases and related risk reduction studies. The research focuses on improving prevention and treatment for conditions such as atherosclerotic cardiovascular disease, atrial fibrillation, peripheral arterial disease, and heart failure, with many trials aimed at lowering major cardiovascular events and refining long-term care.

  • Testing new therapies to reduce the risk of heart attack, stroke, and other serious vascular events
  • Studying rhythm control and stroke prevention in atrial fibrillation
  • Evaluating treatments for lipid disorders and elevated lipoprotein(a)
  • Assessing better approaches for patients with peripheral artery disease and broader cardiovascular risk

These studies combine prevention, symptom control, and outcome improvement, reflecting a strong emphasis on practical advances in everyday cardiology.

Oncology and Hematology

The site is also a busy center for oncology and hematology research, covering cancers such as non-small cell lung cancer, breast cancer, colorectal cancer, prostate cancer, and blood cancers including chronic lymphocytic leukemia, lymphoma, and multiple myeloma. Many trials aim to improve survival, delay progression, and support more personalized treatment choices.

  • Exploring new cancer treatments and combinations for advanced solid tumors
  • Improving outcomes in lung cancer, breast cancer, and colorectal cancer
  • Studying targeted and immune-based approaches in lymphoma and leukemia
  • Testing biomarker-guided strategies to match patients with more effective therapies

Research at Stichting Martini Ziekenhuis includes both treatment effectiveness and ways to tailor care more closely to the biology of each disease.

Respiratory and Critical Care Research

Clinical trials in respiratory diseases and intensive care examine conditions such as COPD, asthma, pulmonary sarcoidosis, and acute respiratory tract infection. The research also includes studies in critically ill patients, aiming to improve recovery, reduce complications, and support better hospital care.

  • Evaluating new treatments for COPD and asthma
  • Comparing therapies for pulmonary sarcoidosis to improve disease control
  • Testing interventions for hospitalized patients with acute respiratory infection
  • Studying care strategies for adults admitted to the intensive care unit

These projects focus on both symptom relief and better clinical outcomes, especially for patients with serious breathing problems or critical illness.

Digestive, Colorectal, and Surgical Innovation

Another important area at the site is gastrointestinal and surgical research, especially in rectal cancer, esophageal cancer, and early-stage colorectal disease. Trials often look at organ-preserving treatment, improved cancer control, and better surgical visualization or recovery.

  • Testing organ-preserving strategies for early rectal cancer
  • Evaluating adjuvant approaches to reduce recurrence after surgery for rectal cancer
  • Improving surgical guidance and anatomical visualization during abdominal procedures
  • Studying new approaches for esophageal cancer and related digestive system cancers

This work reflects a strong interest in balancing effective cancer treatment with quality of life and function after therapy.

Metabolic, Endocrine, and Kidney Health

The research portfolio also includes metabolic, endocrine, and kidney disease studies. Key conditions include obesity, gestational diabetes, hyperthyroidism, and chronic kidney disease, with trials designed to improve disease management and reduce long-term complications.

  • Investigating better care for gestational diabetes during and after pregnancy
  • Studying treatments for chronic kidney disease and related cardiovascular risk
  • Comparing options for hyperthyroidism to support safer thyroid control
  • Evaluating therapies aimed at lowering weight-related and metabolic risk

These studies show an emphasis on prevention, chronic disease management, and protecting organ function over time.

Immunology, Rheumatology, and Infectious Disease

Research at Stichting Martini Ziekenhuis also spans immune system diseases, rheumatology, and infectious diseases. Trials address conditions such as primary progressive multiple sclerosis, ACPA positive arthralgia, rheumatoid arthritis risk, Staphylococcus aureus bacteremia, and other serious infections, with the goal of improving early detection and treatment response.

  • Testing new approaches for multiple sclerosis and inflammatory disease
  • Studying markers that may predict progression to arthritis
  • Evaluating treatments for serious bloodstream and respiratory infections
  • Exploring immune-related strategies to improve diagnosis and care

This area combines prevention, biomarker research, and treatment evaluation across both chronic inflammatory disease and acute infection.

Women's Health and Reproductive Medicine

The site contributes to women’s health research through studies in contraception, pregnancy-related conditions, and vulvar disease. These trials aim to improve safety, effectiveness, and recurrence prevention in areas that directly affect reproductive and gynecologic health.

  • Assessing new contraceptive options for women
  • Improving care for gestational diabetes mellitus
  • Testing ways to prevent recurrence of vulvar high-grade squamous intraepithelial lesion
  • Supporting broader reproductive and urinary health research

The focus is on practical solutions that can improve everyday care for women across different stages of life.

Advanced Imaging, Diagnostics, and Quality of Care

A distinct part of the portfolio involves diagnostic techniques, medical imaging, and health care quality research. These studies look at better ways to identify disease, predict outcomes, and support more precise treatment decisions across several specialties.

  • Developing imaging tools to improve detection and monitoring of disease
  • Studying diagnostic markers for cancer, inflammatory disease, and cardiovascular risk
  • Evaluating methods that may improve the quality and efficiency of care
  • Exploring tools that help clinicians choose the most appropriate treatment path

This research supports a more accurate and patient-centered approach to care, linking diagnosis with treatment selection and follow-up.

Site Overview

assignment
68
connected trials
corporate_fare
37
sponsors
science
199
IMPs

Activity Indicator

Last 6 months

6
Trials started
+100% vs previous period.
3
Trials started 6–12 months ago
68
Total trials linked
Highly Active
trending_upGrowing+100%
2
1
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 21 therapeutic areas and 15 of 199 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 194 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
36
Sponsors (total)
37
Active sponsors
24

Sponsor Network

Top 24 by active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 271 other sites in The Netherlands

description
Trial volume
68
Outperforms 87% of sites
public
Therapeutic diversity
21areas
Outperforms 91% of sites
groups
Sponsor diversity
37sponsors
Outperforms 87% of sites

Therapeutic Area Benchmark — The Netherlands

Select a therapeutic area to compare against other sites in The Netherlands.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: The Netherlands

Market Share

Country: The Netherlands

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Stichting Martini Ziekenhuis

lock Showing 1 of 68 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 199 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Pembrolizumab6Unknown2016-07-252026-07-08

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.